AstraZeneca’s development of checkpoint inhibitor ... plus as an added bonus AZ’s drugs were effective in both squamous and non-squamous forms of NSCLC, and didn’t add significantly to ...
AstraZeneca is asking a court to immediately stop generic drugmakers from their plans to make and sell generic forms of ...
Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...
AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
China: In relation to the illegal drug importation allegations, in January 2025, AstraZeneca received a Notice of Transfer to the Prosecutor and an Appraisal Opinion from the Shenzhen City Customs ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed ...
AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...
A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback